3M Drug Delivery Systems and Impel NeuroPharma have announced that the two companies will collaborate on development and commercialization of Impel’s Precision Olfactory Delivery (POD) platform for intranasal delivery of drugs to the central nervous system. No financial terms were disclosed.
Impel CEO Michael Hite commented, “We are pleased to have 3M join our team. We’ve successfully shown that the POD technology is highly effective in the clinic in our ongoing development programs and across diverse therapeutic areas including Alzheimer’s disease, migraine, and pain management. We are proud to have 3M’s key strategic collaboration to support the development and commercialization of the POD platform. With 3M, Impel is better able to empower researchers, physicians, patients, and their families.”
3M DDS President and General Manager Cindy Kent said, “Impel’s POD technology provides an important solution to an unmet need in the drug delivery marketplace. We look forward to supporting Impel as they commercialize the POD technology and expand upon 3M’s leadership in developing novel approaches to major problems confronting the pharmaceutical and biotechnology industries.”
Read the 3M and Impel NeuroPharma press release.
